Blood ammonia measured in μg/mL at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Number Connection Test A, assessed using: seconds (1 trial) or Z‐score (1 trial) at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Health‐related quality of life ‐ all trials Higher scores indicate improved health‐related quality of life · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin probably leads to lower hepatic encephalopathy ‐ total number compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Blood ammonia measured in μg/mL at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Number Connection Test A, assessed using: seconds (1 trial) or Z‐score (1 trial) at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Mortality ‐ total number · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in mortality ‐ total number compared with non‐absorbable disaccharide (low certainty).
1 finding from 1 review
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (low certainty).
1 finding from 1 review
Mortality Mortality at latest · preterm or low birth weight infants
Early (less than seven days following birth) higher showed no clear difference in mortality (latest time reported up to hospital discharge) compared with lower sodium intake (low certainty).
1 finding from 1 review
Hyponatraemia (< 130 mmol/L) · preterm or low birth weight infants
Late (seven days or more following birth) higher may leads to lower hyponatraemia (< 130 mmol/L) compared with lower sodium intake (low certainty).
1 finding from 1 review
Hypernatraemia (≥ 150 mmol/L) · preterm or low birth weight infants
It is very uncertain whether late (seven days or more following birth) higher changes hypernatraemia (≥ 150 mmol/L) compared with lower sodium intake (very low certainty).
1 finding from 1 review
Postnatal growth failure (weight < 10th percentile) · preterm or low birth weight infants
Late (seven days or more following birth) higher may leads to lower postnatal growth failure (weight < 10th percentile) compared with lower sodium intake (low certainty).
1 finding from 1 review
Necrotising enterocolitis · preterm or low birth weight infants
It is very uncertain whether late (seven days or more following birth) higher changes necrotising enterocolitis compared with lower sodium intake (very low certainty).
1 finding from 1 review
Chronic lung disease · preterm or low birth weight infants
It is very uncertain whether late (seven days or more following birth) higher changes chronic lung disease compared with lower sodium intake (very low certainty).
1 finding from 1 review
Mortality Mortality at latest · preterm or low birth weight infants
1 finding from 1 review
Neurodevelopmental disability · preterm or low birth weight infants
1 finding from 1 review
Hyponatraemia (< 130 mmol/L) · preterm or low birth weight infants
1 finding from 1 review
Hypernatraemia (≥ 150 mmol/L) · preterm or low birth weight infants
It is very uncertain whether early and late (day 1 to 28 after birth) higher changes hypernatraemia (≥ 150 mmol/L) compared with lower sodium intake (very low certainty).
1 finding from 1 review